John F. Crowley - 01 Mar 2024 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Reporting relationship: Executive Chairman, Director
Issuer ticker: FOLD
Reported as of: 01 Mar 2024
Net transaction value: -$389,543
SEC form: 4
Accepted by SEC: 05 Mar 2024, 17:14:13 UTC
Prior SEC filing: 20 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Christian Formica, Attorney-in-Fact

Key filing fact

John F. Crowley filed Form 4 for AMICUS THERAPEUTICS, INC. (FOLD) on 05 Mar 2024.

Key facts

This page summarizes John F. Crowley's Form 4 filing for AMICUS THERAPEUTICS, INC. (FOLD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Mar 2024, 17:14.

Change

Previous filing in this sequence was filed on 20 Feb 2024.
Current net transaction value: -$389,543.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FOLD transaction

Common Stock

Sale

Transaction value: $389,543
Shares: -29,181
Change %: -4.8%
Price: $13.35
Shares after: 573,478
Date: 01 Mar 2024
Ownership: Direct
Footnotes: F1

FOLD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 64,895
Date: 01 Mar 2024
Ownership: By Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

John F. Crowley is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.04 to $13.58 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC remarks

All sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2023.